# LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT02652871** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 36 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** LY2510924
- **DRUG:** Idarubicin
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT02652871
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-09
- **Primary completion:** 2019-07-16
- **Final completion:** 2019-07-16
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2019-11-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02652871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02652871, "LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02652871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*